Buy Arcus Biosciences
Amount
Latest price
$8.43
(£1.00 = $1.365)
Number of shares (est.)
0
Start investing today
Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.
Metrics
Market Cap
$896.847M
P/E ratio
-2.00
EPS
-$4.233
Beta
0.88
Dividend rate
N/A
Dividend yield
N/A
About
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
CEO
Dr. Terry J. Rosen, Ph.D.
Employees
627
Sector
Health
Company HQ
HAYWARD, United States of America
Website
News
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $8.63, which was the closing price on June 23, 2025, and restri.
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. “I was very encouraged to see that nearly half of patients had a.
Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript
Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob Goeltz - CFO Juan Jaen - President Conference Call Participants Peter Lawson - Barclays Daina Graybosch - Leerink Partners Yigal Nochomovitz - Citigroup Umer Raffat - Evercore Eva Fortea - Wells Fargo Emily Bodnar - HC Wainwright Operator Hello, everyone. And welcome to Arcus Biosciences First Quarter 2025 Earnings and Financial Results Call.
© 2025 Emma Technologies Ltd. All Rights Reserved.
Emma is registered and incorporated in England and Wales.
Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).
Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.
Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.
Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.
Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.
All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.
Resources: Cancel subscriptions, Cashback offers, Who charged me, Rent Reporting, Budgeting, Investment universe, Emma vs Moneyhub.
Featured cashback offers: Samsung, SimplyCook, NordVPN, Audible, M&S Homeware.